These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19364988)

  • 1. Overview of the 2008 Food and Drug Administration Advisory Committee on safety considerations in the development of ultrasound contrast agents.
    Asch FM; Weissman NJ
    Circulation; 2009 Apr; 119(14):1956-61. PubMed ID: 19364988
    [No Abstract]   [Full Text] [Related]  

  • 2. Product safety compromises patient safety (an unjustified black box warning on ultrasound contrast agents by the Food and Drug Administration).
    Grayburn PA
    Am J Cardiol; 2008 Mar; 101(6):892-3. PubMed ID: 18328861
    [No Abstract]   [Full Text] [Related]  

  • 3. Shiley saga leads to improved communication.
    Farley D
    FDA Consum; 1994; 28(1):12-7. PubMed ID: 10131486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical device recalls from 2004 to 2006: a focus on Class I recalls.
    Villarraga ML; Guerin HL; Lam T
    Food Drug Law J; 2007; 62(3):581-92. PubMed ID: 17915400
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA advisory panel voices persistent safety concerns.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):439. PubMed ID: 16595778
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 7. Postmarketing surveillance for drug safety.
    Holden WL; Scarazzini LJ
    Clin Pharmacol Ther; 2004 Nov; 76(5):503; author reply 504-5. PubMed ID: 15536464
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 9. Report hits FDA to revamp safety oversight.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Jul; 98(13):884-5. PubMed ID: 16818849
    [No Abstract]   [Full Text] [Related]  

  • 10. Achieving meaningful device surveillance: from reaction to proaction.
    Rumsfeld JS; Peterson ED
    JAMA; 2010 Nov; 304(18):2065-6. PubMed ID: 21063018
    [No Abstract]   [Full Text] [Related]  

  • 11. Postmarketing safety reports for human drug and biological products; electronic submission requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jun; 79(111):33072-92. PubMed ID: 24922981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 13. Legal perspectives in causality assessment.
    Freilich WB
    Drug Inf J; 1984; 18(3-4):211-7. PubMed ID: 10268552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond indications: postmarket surveillance and the importance of expanded and off-label use of transcatheter devices in structural and congenital interventions.
    McElhinney DB
    Circ Cardiovasc Interv; 2012 Dec; 5(6):739-40. PubMed ID: 23250968
    [No Abstract]   [Full Text] [Related]  

  • 15. Fort Dodge recalls ProHeart 6, citing FDA safety concerns. Advisory committee to review FDA findings.
    Kuehn BM
    J Am Vet Med Assoc; 2004 Oct; 225(8):1157-8. PubMed ID: 15521431
    [No Abstract]   [Full Text] [Related]  

  • 16. Making medicines safer--the need for an independent drug safety board.
    Wood AJ; Stein CM; Woosley R
    N Engl J Med; 1998 Dec; 339(25):1851-4. PubMed ID: 9854125
    [No Abstract]   [Full Text] [Related]  

  • 17. Study Highlights the Need for Continuing Postapproval Drug Monitoring.
    Stockwell S
    Am J Nurs; 2017 Aug; 117(8):16. PubMed ID: 28749872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical device epidemiology and surveillance: patient safety is the bottom line.
    Brown SL; Bright RA; Tavris DR
    Expert Rev Med Devices; 2004 Sep; 1(1):1-2. PubMed ID: 16293003
    [No Abstract]   [Full Text] [Related]  

  • 19. US FDA contemplates collection of pharmacogenomic data.
    Kling J
    Nat Biotechnol; 2003 Jun; 21(6):590. PubMed ID: 12776133
    [No Abstract]   [Full Text] [Related]  

  • 20. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.